Roche’s Crovalimab matches Soliris, meets Phase 3 trial targets in rare blood disorder

Sunset view on the banks of the Rhine dominated by the Roche tower in Switzerland

trabantos/iStock via Getty Images

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) said their drug crovalimab met the primary goal of a phase 3 study and helped control disease in patients with paroxysmal nocturnal hemoglobinuria (PNH) who had never been treated with this drug.


News7F: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button